Panbela Therapeutics Insider-Eigentum
Was ist das Insider-Eigentum von Panbela Therapeutics?
Insider-Eigentum von Panbela Therapeutics Inc. ist 14.55%
Was ist die Definition von Insider-Eigentum?
Das Insider-Eigentum wird berechnet als die Gesamtzahl der Aktien, die sich im Besitz von Insidern (Anteilseignern, die mehr als 5% der Gesellschaft oder eines leitenden Angestellten oder Direktors der Gesellschaft besitzen), dividiert durch die Gesamtzahl der ausstehenden Aktien.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider-Eigentum von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Panbela Therapeutics
Was macht Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Unternehmen mit insider-eigentum ähnlich Panbela Therapeutics
- Rimini Street hat Insider-Eigentum von 14.50%
- Casper Sleep Inc hat Insider-Eigentum von 14.50%
- Xali Gold Corp hat Insider-Eigentum von 14.50%
- Terra Tech hat Insider-Eigentum von 14.52%
- Sylla Gold Corp hat Insider-Eigentum von 14.52%
- Baron Oil Plc hat Insider-Eigentum von 14.53%
- Panbela Therapeutics hat Insider-Eigentum von 14.55%
- Allied Healthcare Product hat Insider-Eigentum von 14.55%
- Vikas WSP hat Insider-Eigentum von 14.56%
- United (Martins Ferry, OH) hat Insider-Eigentum von 14.58%
- Greenstone Capital hat Insider-Eigentum von 14.59%
- Longboat plc hat Insider-Eigentum von 14.59%
- United Security Bancshares (CA) hat Insider-Eigentum von 14.59%